Aptevo Therapeutics Inc (NASDAQ:APVO) does about 5.75M shares in volume on a normal day but saw 2263292 shares change hands in the recent trading day. The company now has a market cap of 2.31M USD. Its current market price is $0.25, marking a decrease of -0.69% compared to the previous close of $0.25. The 52 week high reached by this stock is $15.14 whilst the lowest price level in 52 weeks is $0.14.
Aptevo Therapeutics Inc (APVO) has a 20-day trading average at $0.1886 and the current price is -98.38% off the 52-week high compared with 77.68% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2610 and its 200-day simple moving average is $2.1367. If we look at the stock’s price movements over the week, volatility stands at 50.30%, which decreases to 19.33% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 53.95 to suggest the stock is neutral.
The consensus objective for the share price is $8.00, suggesting that the stock has a potential upside of 96.88% over the period.
The current price level is 30.02%, -6.04%, and -88.52% away from its SMA20, SMA50, and SMA200 respectively, with the APVO price moving above the 50-day SMA on current market day. Aptevo Therapeutics Inc (APVO) stock is up 23.53% over the week and 36.22% over the past month. Its price is -96.92% year-to-date and -98.29% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -22 above consensus estimates by 11. The company’s next earnings report forecasts estimating quarterly EPS at -3.35 and -17.23 for whole year.
To reach the target analysts have set, the stock logically needs to grow 96.88 percent from here.
Outstanding shares total 9.42M with insiders holding 0.04% of the shares and institutional holders owning 14.61% of the company’s common stock. The company has a return on investment of -263.01% and return on equity of -243.74%. The beta has a value of 5.14. Price to book ratio is 0.22.
